Autism Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
Dallas, TX (PRWEB) January 23, 2015 -- The report "Autism - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Autism. Autism is known as a multifarious developmental disability. Autism disorder is characterized by social activities, non-verbal communication and repetitive behavior. Autism is highly transmissible but the cause includes both environmental factors and genetic susceptibility. It has long been assumed that there is a common cause at the genetic, cognitive and neural levels for autism's characteristic triad of symptoms. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/autism-pipeline-review-h1-2015-market-report.html .
It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. Companies discussed in this Autism Pipeline Review H1 2015 report include Addex Therapeutics Ltd, Avanir Pharmaceuticals, Inc., BioCrea GmbH, BrainStorm Cell Therapeutics Inc., Cellceutix Corporation, Confluence Pharmaceuticals LLC, Curemark, LLC, Edison Pharmaceuticals, Inc., Egenix, Inc., F. Hoffmann-La Roche Ltd., Heptares Therapeutics Ltd., Intra-Cellular Therapies, Inc., MedDay, Merz Pharma GmbH & Co. KgaA, Mitsubishi Tanabe Pharma Corporation, Mnemosyne Pharmaceuticals, Inc., Novartis AG, Omeros Corporation, Otsuka Holdings Co., Ltd., Reviva Pharmaceuticals Inc., Saniona AB, Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries Limited.
The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles featured in the report undergo periodic updating following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269525 . (This is a premium report priced at US$2000 for a single user License.)
Table of Contents
List of Tables
Number of Products under Development for Autism, H1 2015
Number of Products under Development for Autism - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Autism - Pipeline by Addex Therapeutics Ltd, H1 2015
Autism - Pipeline by Avanir Pharmaceuticals, Inc., H1 2015
Autism - Pipeline by BioCrea GmbH, H1 2015
Autism - Pipeline by BrainStorm Cell Therapeutics Inc., H1 2015
Autism - Pipeline by Cellceutix Corporation, H1 2015
Autism - Pipeline by Confluence Pharmaceuticals LLC, H1 2015
Autism - Pipeline by Curemark, LLC, H1 2015
Autism - Pipeline by Edison Pharmaceuticals, Inc., H1 2015
Autism - Pipeline by Egenix, Inc., H1 2015
Autism - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Autism - Pipeline by Heptares Therapeutics Ltd., H1 2015
Autism - Pipeline by Intra-Cellular Therapies, Inc., H1 2015
Autism - Pipeline by MedDay, H1 2015
Autism - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2015
Autism - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015
Autism - Pipeline by Mnemosyne Pharmaceuticals, Inc., H1 2015
Autism - Pipeline by Novartis AG, H1 2015
Autism - Pipeline by Omeros Corporation, H1 2015
Autism - Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Autism - Pipeline by Reviva Pharmaceuticals Inc., H1 2015
Autism - Pipeline by Saniona AB, H1 2015
Autism - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015
Autism - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Autism Therapeutics - Recent Pipeline Updates, H1 2015
Autism - Dormant Projects, H1 2015
Autism - Dormant Projects (Contd..1), H1 2015
Autism - Discontinued Products, H1 2015
Explore more reports on Central Nervous System (CNS) therapeutics therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/central-nervous-system-cns-therapeutics .
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Ritesh Tiwari, RnRMarketResearch, http://www.rnrmarketresearch.com, +1 (888) 391-5441, [email protected]
Share this article